Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Lamanova Olesya Nikolaevna and Filatova E V
NRICP - Centre for Radiosurgery and Radiation Therapy, Novosibirsk, Russian Federation
Posters & Accepted Abstracts: J Hematol Thrombo Dis
Cardiovascular diseases (CVD) and cancer are one of the leading causes of mortality in the world. Radiation therapy of the mediastinum is one of the cases of CVD. Over last 10 years of diagnostic and treatment methods have increased lifetime of the patients. Since, mediastinal lymphoma has positioning near the heart and radiation dose captures it, the risk is greatest in young patients (up to 40 years), who undergo radiotherapy and in the subsequent, they have mortality due to cardiac complications within first five years after the exposure. The interval between exposure and development of pathologists usually exceeds 7-10 years. Mediastinal lymphoma is �?¢�?�?�?�?mobile region�?¢�?�?�? and when the patient is breathing �?¢�?�?�?�?target�?¢�?�?�? is shifting. That is very important thing- breath (or movement of the chest wall), which can change �?¢�?�?�?�?target position�?¢�?�?�? about critical structures (heart, lungs, spinal cord, and esophagus). That is way, the procedure irradiating of mediastinal lymphoma without breathing control has high risk. Using radiotherapy treatment with breath-holding system, for example, Active Breathing Coordinator system- ABC, is advanced method. It can reduce radiation dose to the heart. We did research in our clinic and used ABC and Elekta Axesse linac for treatment of mediastinal lymphoma. We got very good results which were based on dose distribution to the heart, not more than 17 Gy, regardless from lymphoma positioning and size. It is very good indicator, exceptionally for patients with cardiac disease.
Email: o_lamanova@meshalkin.ru